Noah Davidsohn, Ph.D., is Co-Founder and Chief Scientific Officer at Rejuvenate Bio, a Harvard-spinout gene therapy company pioneering treatments for chronic age-related diseases in both humans and companion animals.

Noah earned his undergraduate degree in Applied Physics from Caltech, completed his Ph.D. in Biological Engineering (Synthetic Biology) at MIT, and conducted postdoctoral research in George Church's lab at Harvard's Wyss Institute, where Rejuvenate Bio was born.

An expert in recombinant DNA, viral vector production, and advanced disease modeling, Noah led the first published study to demonstrate epigenetic reprogramming extending overall lifespan in normal wild-type mice, achieving a 109% increase in median remaining lifespan.

Prior to co-founding Rejuvenate Bio, Noah served as a Research Scientist at the Wyss Institute for Biologically Inspired Engineering at Harvard, translating age-reversal discoveries from bench to therapeutic pipeline.

Rejuvenate Bio has raised over $19M in funding, secured a $6M strategic R&D collaboration with Merck Animal Health, received a $4M CIRM grant, and demonstrated real-world reversal of cardiac disease in dogs with three years of safety data and zero adverse events.